Patient-Reported Outcomes clinical trials

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

This study is looking at adding a new drug called Nivolumab to standard chemotherapy for nasopharyngeal cancer. It aims to see if this combination helps more patients achieve a complete response, meaning the cancer is no longer detectable, especially when seen on scans.